Trials / Completed
CompletedNCT04953000
A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A
Local, Multicenter, Non-interventional, Ambispective Study in Severe Hemophilia A Patients on Standard and PK-tailored Prophylaxis With Octocog Alfa (Advate®) in the Russian Federation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 94 (actual)
- Sponsor
- Takeda · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to learn about changes in the lowest blood levels of Factor VIII in men and boys when upgraded from standard prophylaxis with Advate to individualized prophylaxis with Advate. No study medicines will be provided to participants in this study. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 3 times in total during the study. During these visits, study data will be collected by the study doctor.
Detailed description
Local, Multicenter, Non-interventional, Ambispective Study in Severe Hemophilia A Patients on Standard and PK-tailored Prophylaxis With Octocog Alfa (Advate®) in the Russian Federation
Conditions
Timeline
- Start date
- 2021-08-19
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
- First posted
- 2021-07-07
- Last updated
- 2023-07-11
Locations
13 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04953000. Inclusion in this directory is not an endorsement.